-
COST-UTILITY ANALYSIS OF FLURBIPROFEN VERSUS LOXOPROFEN SODIUM CATAPLASMS IN KNEE OSTEOARTHRITIS: EVIDENCE FROM A PHYSICIAN-PHARMACIST COLLABORATIVE RANDOMIZED TRIAL
Aug 11, 2026, 17:16 PM -
SHIFTING THE COVID-19 VACCINE LANDSCAPE WITH LOWER REACTOGENICITY: BUDGET IMPACT OF NUVAXOVID IN UK OLDER ADULTS
Aug 11, 2026, 17:16 PM -
TARGETED SINGLE-RULE EXCLUSION SCREENERS FOR SYSTEMATIC AND TARGETED LITERATURE REVIEWS: SMALL LLMS REACH HIGH PRECISION ON RECURRING ELIGIBILITY CRITERIA
Aug 11, 2026, 17:16 PM -
ANNUAL DIRECT MEDICAL COST OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES IN TURKIYE: A PUBLIC PAYER MICRO-COSTING ANALYSIS
Aug 11, 2026, 17:16 PM -
WHY TWO BRANDS FOR ONE MOLECULE? STRATEGIC IMPLICATIONS OF DUAL-BRAND APPROACHES FOR ORPHAN DESIGNATIONS, REVENUE THRESHOLDS AND PRICING IN GERMANY
Aug 11, 2026, 17:16 PM -
SYSTEMATIC LITERATURE REVIEW AND CRITICAL APPRAISAL OF COST-EFFECTIVENESS MODELS OF ANTIMICROBIAL TREATMENTS
Aug 11, 2026, 17:16 PM -
REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN ADVANCED/METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH AND WITHOUT ACTIONABLE GENOMIC ALTERATIONS: A POPULATION-BASED COHORT STUDY IN ENGLAND, 2017-2025
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATIONS OF NON-PHARMACOLOGIC MANAGEMENT FOR CONGESTIVE HEART FAILURE: A SYSTEMATIC REVIEW
Aug 11, 2026, 17:16 PM -
LONGITUDINAL TRENDS IN MORTALITY AGE AMONG PATIENTS WITH SICKLE CELL DISEASE: REAL-WORD DATA (2013-2024)
Aug 11, 2026, 17:16 PM -
INCLUSION OF CAREGIVER QUALITY-OF-LIFE IN ECONOMIC EVALUATIONS: GLOBAL HTA PERSPECTIVES AND IMPACT
Aug 11, 2026, 17:16 PM -
PROVISIONAL AND TIME-LIMITED ACCESS PATHWAYS - A COMPARATIVE ANALYSIS OF CANADA, UK, EU, AND AUSTRALIA
Aug 11, 2026, 17:16 PM -
HOW CAN WE APPROACH WHOLE HEALTH USING DIGITAL BIOMARKERS AND ENDPOINTS FROM CONSUMER WEARABLES?
Aug 11, 2026, 17:16 PM -
AGREEMENT BETWEEN ARTIFICIAL INTELLIGENCE AND HUMAN ASSESSMENT IN QUALITY APPRAISAL OF ECONOMIC EVALUATIONS USING THE DRUMMOND CHECKLIST
Aug 11, 2026, 17:16 PM -
A DISCRETE EVENT SIMULATION MODEL FOR THE HEALTH ECONOMIC EVALUATION OF A RAPID AI-GUIDED WHOLE-GENOME SEQUENCING PLATFORM FOR THE DIAGNOSIS OF ESKAPEE BLOODSTREAM INFECTIONS: MODEL DEVELOPMENT AND METHODOLOGY
Aug 11, 2026, 17:16 PM -
OBSTRUCTIVE SLEEP APNEA, PHYSICAL ACTIVITY, AND RISK OF INCIDENT CHRONIC KIDNEY DISEASE: A PROSPECTIVE COHORT STUDY FROM THE UK BIOBANK
Aug 11, 2026, 17:16 PM -
IMPACT OF SURGICAL TIMING AND PRE-INCISION ANTIBIOTICS ON MATERNAL AND NEONATAL OUTCOMES IN EMERGENCY CESAREAN SECTIONS: A PROSPECTIVE STUDY
Aug 11, 2026, 17:16 PM -
HOW MUCH DO MEDICATIONS COST PATIENTS IN FINLAND? A NATIONWIDE REGISTER-BASED STUDY OF OUT-OF-POCKET COSTS
Aug 11, 2026, 17:16 PM -
FASTER, MOSTLY FAITHFUL: CAN AI REPRODUCE MANUAL PICO EXTRACTION IN PREPARATION FOR EU JCA?
Aug 11, 2026, 17:16 PM -
ONE CONCEPT, MANY COHORTS: IMPACT OF COHORT PHENOTYPE DEFINITIONAL VARIANCE IN DEPRESSION, MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION ON REAL-WORLD RESEARCH
Aug 11, 2026, 17:16 PM -
SHORT- AND MID-TERM OUTCOMES OF TEVAR IN DESCENDING THORACIC AORTIC PATHOLOGIES: INSIGHTS FROM A FRENCH NATIONWIDE COHORT
Aug 11, 2026, 17:16 PM
